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Abstract
Vasospasm refers to a condition in which an arterial spasm leads to vasoconstric-
tion. This can lead to tissue ischemia and necrosis. Coronary vasospasm can lead 
to significant cardiac ischemia associated with symptomatic ischemia or cardiac 
arrhythmia. Cerebral vasospasm is an essential source of morbidity and mortality 
in subarachnoid hemorrhage patients. It can happen within 3–15 days with a peak 
incidence at 7 days after aneurysmal subarachnoid hemorrhage (SAH). Calcium 
channel blockers are widely used in the treatment of hypertension, angina pectoris, 
cardiac arrhythmias, and other disorders like SAH vasospasm related and Migraine. 
The specific treatment of cerebral vasospasm helps improving cerebral blood flow 
to avoid delayed ischemic neurologic deficit by reducing ICP, optimizing the rate 
of cerebral oxygen demand, and enhancing cerebral blood flow with one of the 
following approaches: indirect pharmacological protection of brain tissue or direct 
mechanical dilation of the vasospastic vessel. Nimodipine is the standard of care 
in aneurysmal SAH patients. Nimodipine 60 mg every 4 hours can be used for all 
patients with aneurysmal SAH once the diagnosis is made for 21 days.
Keywords: coronary vasospasm, cerebral vasospasm, calcium channel blockers, 
cerebral blood flow, nimodipine
1. Introduction
Vasospasm is a condition which is associated with an arterial spasm and vasocon-
striction, which may lead to tissue ischemia and necrosis. Coronary vasospasm can 
lead to significant cardiac ischemia associated with symptomatic ischemia or cardiac 
arrhythmia. Cerebral vasospasm may arise as a complication of subarachnoid hem-
orrhage (SAH). The most common cause of delayed cerebral ischemia after SAH is 
assumed to be vasospasm; delayed cerebral ischemia contributes substantially to 
morbidity and mortality after SAH especially aneurysmal SAH. Calcium channel 
blockers are widely used in the treatment of hypertension, angina pectoris, cardiac 
arrhythmias, and other disorders like SAH vasospasm related and migraine. Data is 
suggesting that their use reduces the risk of subsequent cardiovascular events [1, 2]. 
Besides, some meta-analyses have suggested that calcium channel blockers may be 
more effective than other drugs in reducing stroke risk [3, 4]. Fleckenstein’s work in 
the 1960s led to the concept that drugs alter cardiac and smooth muscle contraction 
by blocking the entry of Ca2+ into myocytes. Godfraind and associates showed that 
the effect of the diphenylpiperazine analogs in the prevention of agonist-induced 
vascular smooth muscle contraction could be overcome by raising the concentration 
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of Ca2+ in the extracellular medium. Hass and Hartfelder reported in 1962 that 
verapamil, a coronary vasodilator, possessed negative inotropic and chronotropic 
effects that were not seen with other vasodilatory agents, such as GTN. In 1967, 
Fleckenstein suggested that the negative inotropic effect resulted from an inhibition 
of excitation-contraction coupling and that the mechanism involved reduced move-
ment of Ca2+ into cardiac myocytes. Verapamil was the first clinically available Ca2+ 
channel blocker; it is a congener of papaverine. Many other Ca2+ entry blockers with 
a wide range of structures are now available [5].
2. Mechanism of action and effects
Calcium is an essential element for excitation-contraction coupling in muscle 
cells. The increase in the cytosolic Ca2+ concentration leads to an increased contrac-
tion in both cardiac and vascular smooth muscle cells [6]:
1. In smooth muscle and cardiac muscle cells, Ca2+ can enter cells through  
transmembrane voltage-gated and ligand-gated channels (Figures 1 and 2).
2. In striated and cardiac muscle cells, a rise in intracellular free Ca2+ promotes 
the release of further Ca2+ from the sarcoplasmic reticulum (SR) through  
actions at ryanodine receptors (Figures 1 and 2).
3. Ligand-gated channels linked to G-protein-coupled receptors promote the 
release of Ca2+ from intracellular stores in the sarcoplasmic reticulum.
4. Ca2+ leaves striated and cardiac muscle cells in exchange for Na + via the  
Na+/Ca2+ exchanger (Figure 1).
Therefore, in striated muscle, free Ca2+ in the cytosol comes only from the 
sarcoplasmic reticulum, while in smooth muscle, it must enter the cell through 
transmembrane Ca2+ channels. Cardiac muscle uses both mechanisms.
Four types of transmembrane calcium channels, differing in location and 
function, have been identified:
A. L type, located in skeletal, cardiac, and smooth muscles, causing contraction 
of muscle cells.
B. T type, found in pacemaker cells, causing Ca2+ entry, inactivated at more nega-
tive potentials and more rapid than the L type.
C. N type is available in neurons and acting in transmitter release.
D. P type is in Purkinje cells whose function is unknown currently.
5- Voltage-gated L-type Ca2+ channels (long-acting, high threshold-activated, 
slowly inactivated) are found in the cell membranes of a large number of excitable 
cells, including cardiac and vascular smooth muscle. Ca2+ enters the cell through 
these channels when the cell membrane is depolarized. The cardiac and vascular 
smooth muscle L-type Ca2+ channels have different subunit structures. L-type 
channels are essential therapeutically. The L-type calcium channel, acted on by cal-
cium channel blockers, consists of five different subunits (α1, α2, β, δ, γ). Figure 3 
represents the L type of Ca2+ channel [7].
3Calcium Channel Blockers
DOI: http://dx.doi.org/10.5772/intechopen.90778
6- Voltage-gated T-type Ca2+ channels (transient, low threshold-activated, fast 
inactivated) are found in pacemaker cells of the sinoatrial and atrioventricular 
nodes and are also present in vascular smooth muscle. Calcium channel blockers 
Figure 2. 
Mechanism of contraction of the cardiac myocyte by L-type voltage-gated Ca channel.
Figure 3. 
Subunits of the L-type calcium channel.
Figure 1. 
Regulation of calcium in cardiac myocytes and blood vessels.
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have different chemical structures, but their standard action is to reduce Ca2+ influx 
through voltage-gated L-type Ca2+ channels in smooth cardiac muscle (Figure 2).
There are clinically significant differences among the different types of calcium 
channel blockers, which bind to discrete receptors on the L-type Ca2+ channel. The 
receptor for verapamil is intracellular, while diltiazem and the dihydropyridines 
(e.g., nifedipine, amlodipine) have extracellular binding sites; however, the recep-
tor domains for verapamil and diltiazem overlap. Verapamil and diltiazem exhibit 
frequency-dependent receptor binding and gain access to the Ca2+ channel when 
it is in the open state; in contrast, the dihydropyridines preferentially bind to the 
channel in its inactivated state. As more Ca2+ channels are in the inactive state, dihy-
dropyridines selectively bind to Ca2+ channels in vascular smooth muscle. These 
receptor binding characteristics account for the relative vascular selectivity of the 
dihydropyridines and the antiarrhythmic properties of verapamil and diltiazem [6].
Calcium concentrations in cardiac cells and vascular smooth muscles are under 
the influence of different mechanisms. Calcium entry through voltage-gated L-type 
Ca2+ channels stimulates ryanodine receptors (RyR) in the sarcoplasmic reticulum, 
releasing stored Ca2+ (a process known as Ca2+ −induced calcium release, CICR). 
Intracellular Ca2+ is also regulated by exchange with Na + via the Na+/Ca2+ exchang-
ers (NCX) in the cell membrane.
The depolarization phase during the action potential activates the voltage-gated 
channels, and the influx of Ca2+ into the cell results in myosin phosphorylation and 
muscle contraction. It also promotes further Ca2+ release from the sarcoplasmic 
reticulum by stimulation of ryanodine receptors. L-type Ca2+ channels can, there-
fore, be reduced directly by calcium channel blockers.
3. Pharmacokinetics
Most calcium channel blockers are lipophilic compounds with similar phar-
macokinetic properties. Calcium channel blockers are typically administered in 
oral dosage forms, but orally administered calcium channel blockers undergo 
significant first-pass metabolism in the gut and liver, which can significantly reduce 
bioavailability to 10–30%. Most oral calcium channel blockers have a rapid onset 
of action between 20 minutes and 2 hours like nifedipine resulting in reflex tachy-
cardia, which can worsen myocardial ischemia due to shortening diastolic phase 
of the cardiac cycle. Most of the agents typically have short elimination half-lives 
(2–10 hours), necessitating short dosing intervals or extended-release formations. 
Amlodipine was developed in an attempt to overcome the pharmacokinetic limita-
tions of nifedipine. This drug has an increased oral bioavailability of 60%. The time 
of onset is 6 hours, and prolonged elimination half-life is 40 hours. These kinetic 
properties are likely due, in part, to its lipophilic character and its positive charge 
at physiologic pH, which leads to increased association with negatively charged 
plasma membranes. Some of the calcium channel blockers also have intravenous 
formulations like diltiazem and verapamil, while clevidipine is a dihydropyridine 
agent that is available only as an intravenous formulation. All calcium channel 
blockers are metabolized by the liver. Diltiazem is primarily excreted by the liver, 
while dihydropyridines and verapamil are mainly excreted in the urine [6–8].
4. Pharmacological actions
The main targets of calcium channel blockers are vascular tissue and cardiac 
cells. Ca2+ channel blockers inhibit the voltage-dependent Ca2+ channels in vascular 
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smooth muscle and decrease Ca2+ entry. All Ca2+ channel antagonists relax arterial 
smooth muscle and thereby reduce arterial resistance, blood pressure, and cardiac 
afterload. Ca2+ channel blockers do not influence cardiac preload significantly when 
given at regular doses, suggesting that capacitance veins that determine venous 
return to the heart are resistant to the relaxing effect of Ca2+ channel antagonists. 
Depolarization in the SA and AV nodes depends mainly on the movement of Ca2+ 
through the slow channel. The impact of a Ca2+ channel blocker on AV conduction 
and the rate of the sinus node pacemaker depend on whether the agent delays the 
recovery of the slow channel.
Diltiazem and verapamil decrease the rate of the SA node pacemaker and slow 
AV conduction at clinically used doses; the latter effect is the basis for their use in 
the treatment of supraventricular tachyarrhythmias [6–8].
5. Cardiovascular effects of different Ca2+ channel blockers
The hemodynamic profiles of the Ca2+ channel blockers approved for clinical use 
differ and depend mainly on the ratio of vasodilating and negative inotropic and 
chronotropic effects on the heart (Table 1, Figures 4 and 5). Although all calcium 
channel blockers are vasodilators, dihydropyridine derivatives such as nifedipine 
and amlodipine are the most potent and have the most significant vascular selectiv-
ity. Arterial dilation reduces peripheral resistance and lowers blood pressure, which 
reduces the work of the left ventricle and therefore reduces myocardial oxygen 
demand. Most dihydropyridines have a rapid onset of action. A rapid reduction 
in blood pressure can lead to reflex sympathetic nervous system activation and 
tachycardia. Amlodipine or modified-release formulations of short-acting dihydro-
pyridines are more slowly absorbed and gradually reduce blood pressure with little 
reflex tachycardia. But generally, the differences between the relatively vaso-selec-
tive dihydropyridines and the much less-selective diltiazem and verapamil have 
essential consequences because the decrease in arterial blood pressure elicits reflex 
sympathetic activation, resulting in the stimulation of heart rate, AV conduction 
velocity, and myocardial force, just the opposite of the direct effect of Ca2+ channel 
blockers. While direct and indirect impacts usually balance each other in the case 
of verapamil and diltiazem, sympathetic stimulation often prevails in dihydropyri-
dines, causing an increase in heart rate and contractility. Cardiac depressant effects 
Table 1. 
Comparative cardiovascular effects of calcium channel blockers graded from 0 (no effect) to 5 (prominent 
effect).
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of dihydropyridines may be unmasked, though, in the presence of β blockers and 
patients with heart failure.
Also, they can have a significant impact on coronary artery dilation; for this 
reason, CCB can prevent or relieve coronary vasospasm and improve myocardial 
blood flow. On the other hand, CCBs have negative chronotropic effect. Verapamil 
and diltiazem (but not the dihydropyridines) slow the rate of firing of the sinoatrial 
node and slow the conduction of the electrical impulse through the atrioventricular 
node. Reflex tachycardia does not occur with these drugs, and they also slow the 
rate of rising in heart rate during exercise. CCBs play an essential role in reducing 
cardiac contractility as most calcium channel blockers (particularly verapamil) 
have some negative inotropic effects. Amlodipine does not impair myocardial 
contractility.
Figure 4. 
Effects of calcium channel blocker agents.
Figure 5. 
Calcium channel blocker sites of action.
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6. Calcium channel blocker agents
There are two types of CCBs:
A. Dihydropyridines: amlodipine, clevidipine, felodipine, isradipine, lercanidi-
pine, nicardipine, nifedipine, nimodipine, and nisoldipine
Dihydropyridines exhibit much higher arterial vasodilation than non-
dihydropyridines while having relatively little impact on cardiac tissue (i.e., 
there is less depression on myocardial contractility, less impairment on SA 
node automaticity, and less slowing on AV node conduction velocity) (Table 1, 
Figure 4).
B. Non-dihydropyridines:
• Benzothiazepines (diltiazem)
• Phenylalkylamines (verapamil)
Non-dihydropyridines are more effective in tissue with frequent channel 
openings (i.e., SA node, AV node, and cardiac myocytes), and channel inhibition 
increases in proportion to heart rate. The negative chronotropic and inotropic 
effects on non-dihydropyridine agents appear greater for verapamil than diltiazem. 
The phenylalkylamine verapamil and the benzothiazepine diltiazem have both 
cardiac and vascular actions (Table 1, Figure 4). These drugs have antiarrhythmic, 
antianginal, and antihypertensive activity.
6.1 Nifedipine
It is a dihydropyridine that does not resemble the other calcium antagonists in 
chemical structure. Although it is not a nitrate, its nitro group is essential for its 
antianginal effect. Also, it has peripheral vasodilatory effects. It works by inhibiting 
the voltage-dependent calcium channel in the vascular smooth muscles and has 
little or no direct suppressant effect on the SA or AV nodes. Nifedipine is thought 
to be more effective in patients with coronary vasospasm, and it is usually used for 
vasospastic angina along with angina pectoris.
Additionally, it is used in selected patients to treat hypertension because of its 
vasodilatory properties. Nifedipine has efficient absorption with buccal or oral 
administration. Around 90% of nifedipine is protein-bound. The bioavailability of 
an oral dose reaches 65%. Nifedipine gets metabolized into two inactive metabo-
lites which are found in equilibrium with each other. Only a limited amount of 
unchanged nifedipine is found in the urine [7].
6.2 Amlodipine
Similar to second-generation dihydropyridines, it has a higher selectivity for 
the vascular smooth muscles than the myocardial tissue. It has a longer half-life 
(34 hours) but less negative inotropic effect than nifedipine. It is used in the treat-
ment of chronic stable angina and essential hypertension [7]. Amlodipine increases 
exercise duration, decreases anginal attacks, and reduces the consumption of 
nitroglycerin. It is given once daily (at a dose of 5 or 10 mg). Common side effects 
of the dihydropyridines are less likely with amlodipine.
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6.3 Nicardipine
It is a short-acting dihydropyridine with a side effect profile similar to nife-
dipine; it has also been shown to be useful in angina. It is remarkably effective in 
vasospastic angina.
6.4 Felodipine
It is a second-generation dihydropyridine channel blocker of the nifedipine 
type. It is more selective for vascular smooth muscles than myocardial tissue. And 
it serves as an effective vasodilator. It is usually used in the treatment of angina and 
essential hypertension. Additionally, it exhibits a high degree of protein binding 
and has a half-life ranging from 10 to 18 hours.
6.5 Nimodipine
It is a dihydropyridine calcium channel blocker that differs from other dihydro-
pyridines as it dilates the cerebral blood vessels more than other dihydropyridines 
do. It is indicated in the treatment of subarachnoid hemorrhage-associated neuro-
logical deficits.
6.6 Verapamil
It is a phenylalkylamine. It was introduced in 1962 as a coronary vasodilator. It 
is used for the treatment of angina pectoris, arrhythmias due to ischemic cardiac 
syndromes, and supraventricular arrhythmias as well. Verapamil’s primary effect 
is on the slow Ca2+ channel, which results in a slowing of AV conduction and the 
sinus rate. It has a rapid absorption following oral administration. However, it is 
metabolized quickly and, therefore, has low bioavailability. Its main site of first-
pass metabolism is the liver, forming several products. Yet, its metabolites have 
no significant biological effects. Verapamil has an elimination half-life of around 
5 hours. Verapamil, like the dihydropyridines, causes little impact on venous return 
and preload but has more direct negative inotropic and chronotropic effects than 
the dihydropyridines at doses that produce arteriolar dilation and afterload reduc-
tion (Figure 4). Thus, the consequences of a reflex increase in adrenergic tone 
are generally offset by the direct cardio depressant effects of the drug. In patients 
without heart failure, oral administration of verapamil reduces peripheral vascular 
resistance and blood pressure with minimal changes in heart rate. Ventricular 
performance is not impaired and may improve, especially if ischemia limits perfor-
mance. In contrast, in patients with heart failure, intravenous verapamil can cause 
a marked decrease in contractility and left ventricular function. The antianginal 
effect of verapamil, like that of all Ca2+ channel blockers, is due primarily to a 
reduction in myocardial O2 demand [7].
6.7 Diltiazem
It was introduced in Japan as a cardiovascular agent for the treatment of angina pec-
toris. It was detected to dilate peripheral arteries and arterioles. By relieving coronary 
artery spasm, diltiazem increases myocardial oxygen supply, and by decreasing heart 
rate, it reduces myocardial oxygen demand. It is used in patients with variant angina as 
well. Additionally, it has electrophysiological properties similar to those of verapamil 
and, therefore, is used as an antiarrhythmic agent, but it is less potent than verapamil. 
It has a rapid oral absorption through the digestive tract, and it reaches peak plasma 
9Calcium Channel Blockers
DOI: http://dx.doi.org/10.5772/intechopen.90778
levels within 1 hour of administration. Nevertheless, the sustained-release prepara-
tions provide peak plasma levels within 3–4 hours of oral administration.
Diltiazem is metabolized extensively by the first-pass metabolism after oral 
administration. Hence, its bioavailability is about 40%. It undergoes several bio-
transformations, including deacetylation, oxidative O- and N-demethylations, 
and conjugation of the phenolic metabolites. Although it has various metabolites, 
only deacetyldiltiazem is pharmacologically active, which has about 40–50% of the 
potency of the parent drug [7].
6.8 Side effects
• Headache, flushing, and dizziness due to arterial dilation, although tolerance 
often occurs with continued use.
• Ankle edema probably arises from increased transcapillary hydrostatic pres-
sure. It happens mostly with dihydropyridines, and it is frequently resistant to 
diuretics.
• Decompensated heart failure is due to reduced cardiac contractility, especially 
in patients with preexisting poor left ventricular function, particularly with 
verapamil, but amlodipine does not depress cardiac contractility.
• Tachycardia and palpitations can arise with dihydropyridines, especially with 
rapid-release formulations.
• Bradycardia and heart block can occur with verapamil and diltiazem.
• Constipation is most common with verapamil and less with diltiazem.
• Heartburn associated with Amlodipine and other dihydropyridines use is due 
to lower esophageal sphincter relaxation.
• Gum hyperplasia.
7. Calcium channel blocker indications
7.1 Calcium channel blockers for hypertension
CCBs are prevalent antihypertensive drugs. CCBs lower BP by causing periph-
eral arterial dilation, with the rank order of potency being dihydropyridines > 
diltiazem > verapamil. They are generally well-tolerated, do not require monitoring 
with blood tests, and have proven safe and effective in many large RCTs. CCBs also 
have antianginal and some antiarrhythmic effects and seem to provide more protec-
tion against stroke than other antihypertensive agents do.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack 
Trial (ALLHAT) and subsequent RCTs showed that CCBs (represented by amlodip-
ine) prevent coronary events as effectively as diuretics and RAS blockers do.
7.2 Calcium channel blockers for coronary vasospasm
Coronary spasm results in transient functional occlusion of a coronary artery 
that is reversible with nitrate vasodilation. It occurs in the setting of coronary 
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stenosis. Variant angina results from reduced blood flow (a consequence of tran-
sient localized vasoconstriction) rather than increased O2 demand. Drug-induced 
causes (e.g., cocaine, amphetamines, sumatriptan, and related antimigraine 
drugs) should be excluded. CCBs are effective in about 90% of patients. These 
agents are considered first-line treatment and may be combined with nitrate. The 
effects of pharmacologic vasodilators on coronary flow reflect direct actions on 
vascular smooth muscle as well as secondary adjustments in resistance artery tone. 
All calcium channel blockers induce vascular smooth muscle relaxation and are 
to various degrees pharmacologic coronary vasodilators (Figure 6). In epicardial 
arteries, the vasodilator response is like nitroglycerin and is effective in preventing 
coronary vasospasm superimposed on coronary stenosis as well as in normal arter-
ies of patients with variant angina. They also submaximally vasodilate coronary 
resistance vessels. In this regard, dihydropyridine derivatives such as nifedipine are 
particularly potent and can sometimes precipitate subendocardial ischemia in the 
presence of critical stenosis. This arises from a transmural redistribution of blood 
flow (coronary steal) as well as the tachycardia and hypotension that transiently 
occur with short half-life formulations of nifedipine. One study demonstrated 
that the use of calcium channel blocker therapy was an independent predictor of 
myocardial infarct-free survival in vasospastic angina patients.
7.3 Calcium channel blockers for stable angina
All calcium channel blockers can be used in the treatment of stable angina 
pectoris. They vasodilate coronary arteries, reduce coronary resistance, increase 
coronary blood flow, and may enhance the development of coronary collaterals. The 
vasodilatation and increase in coronary artery blood flow result from the blockade 
of calcium influx as well as an increase in the levels of nitric oxide and bradykinin; 
therefore, the increase in coronary artery blood flow is a result of bradykinin/nitric 
oxide-dependent and bradykinin/nitric oxide-independent mechanisms. They elicit 
a strong reflex beta-adrenergic response, making any potential negative inotropic or 
chronotropic effect clinically insignificant. This adrenergic response often includes 
Figure 6. 
Sites of effects of calcium channel blockers in angina.
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a reflex tachycardia. Verapamil and diltiazem are useful in angina because they 
decrease myocardial oxygen demand by acting as a negative inotropic and chrono-
tropic effect, by lowering the systemic blood pressure, and by lowering heart rate 
by blocking AV node (Figure 6). The use of short-acting dihydropyridines, such as 
nifedipine, can exacerbate ischemia due to reflex tachycardia, and therefore, it can 
be used as a monotherapy in this setting. Calcium channel blockers are used with 
combination therapy with beta-blockers, which can be more effective than either 
therapy alone. Amlodipine or felodipine could be considered before other calcium 
channel blockers, given their better side effect profiles when used in combina-
tion with beta-blockers. In stable angina patients with suspension of a vasoactive 
component, a trial of a calcium channel blocker can be added to beta blocker agents. 
Calcium channel blockers, particularly verapamil and diltiazem, should be used 
with caution in patients with left ventricular systolic dysfunction, such as those 
with an ejection fraction less than 40 percent or heart failure due to their negative 
inotropic effect.
7.4 Calcium channel blockers for acute coronary syndrome
Calcium channel blockers have been effective in reducing ischemia in patients 
with NSTE-ACS and persistent ischemia despite treatment with full-dose nitrates 
and beta-blockers as well as in patients with contraindications to beta-blockers and 
among those with hypertension. Such patients should receive non-dihydropyridine 
calcium channel-blocking agents that lower the heart rate [9, 10].
7.5 Calcium channel blockers for hypertrophic cardiomyopathy (HCM)
Verapamil improves left ventricular outflow obstruction and symptoms in 
patients with HCM.
7.6 Calcium channel blockers in the treatment of cardiac arrhythmias
Calcium channel blockers (CCBs) are useful antiarrhythmic agents in the 
management of certain arrhythmias, primarily supraventricular tachyarrhythmias. 
Verapamil is the drug of choice to terminate idiopathic fascicular ventricular 
tachycardia.
7.7 Calcium channel blockers for migraine
Verapamil can be used in the prevention of migraine headaches but is considered 
a second-choice drug.
7.8 Calcium channel blockers for aneurysmal subarachnoid hemorrhage
It is essential to review the cause behind intracranial arterial spasm, mecha-
nisms, diagnostic tools, and management to understand the role of CCBs in vaso-
spasm among patients with aneurysmal subarachnoid hemorrhage.
Vascular calcification is specific for arteries, which can involve all arteries, 
including the carotid artery and cerebral arteries. Intracranial arterial calcification 
(IAC) was first detected in the early 1960s. It is associated with atherosclerosis, espe-
cially in older people. Vascular calcification is an integral part of the active process 
of atherosclerosis, occurring in up to 90% of atherosclerotic lesions. Recent clinical 
studies have consistently found the intracranial internal carotid artery (IICA) to be 
the most common site of IAC. The incidence of IICA calcification has been reported 
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to range from 60 to 90% according to ethnicity, age, and stroke or other risk factors. 
The vertebral artery is the second most common artery affected by calcification, 
while other arteries have been affected only by less than 5%. An unenhanced CT 
scan is the most accessible and direct method to evaluate IAC in patients.
The prevalence of intracranial artery calcification is:
• Internal carotid artery: 60%
• Vertebral artery: 20%
• Middle cerebral artery: 5%
• Basilar artery: 5%
Risk factors of intracranial artery calcification:
Advanced age.
Diabetes mellitus.
Hypercholesterolemia.
Hypertension.
History of cardiovascular disease.
Excessive alcohol intake.
End-stage renal disease with long duration of hemodialysis [11–13].
7.8.1 Hemodynamic and clinical effects of IAC
IAC can lead to three significant hemodynamic effects: Firstly, it can lead to 
increase the arterial stiffness. This phenomenon is associated with aging and accel-
erated by other vascular risk factors. It can be measured by the pulse wave velocity 
(PWV) and may indicate early atherosclerotic changes. Several studies have verified 
the correlation between IAC and arterial stiffness, and this may increase the risk 
of stroke. Secondly, arterial stenosis can be linked to arterial calcification, which 
may lead to ischemic stroke due to direct luminal stenosis. Thirdly, IAC may lead 
to plaque stability. Intravascular ultrasound studies found heavily calcified plaques 
to be more resistant to plaque progression. Therefore, the findings for CAC suggest 
that substantial calcification may help stabilize atherosclerotic plaques. Also, a 
heavy plaque burden hidden in heavily calcified arteries may partially account for 
the association between severe arterial calcification and ischemic events regardless 
of plaque vulnerability.
7.8.2 Vasospasm and delayed cerebral ischemia
Cerebral vasospasm is an essential source of morbidity and mortality in 
subarachnoid hemorrhage patients. Vasospasm is one of the most common acute 
complications. It can happen within 3–15 days with a peak incidence at 7 days after 
aneurysmal SAH. Symptomatic vasospasm occurs in 20–40% of subarachnoid hem-
orrhage cases and is considered as the least understood component in their care. 
The symptom severity depends upon the artery affected and the degree of collateral 
circulation. Strokes from vasospasm account for nearly 50% of the early deaths in 
patients who survive the initial subarachnoid hemorrhage treatment. It is character-
ized by a pathological; diffuse, affecting all layers of the involved arterial wall; and 
long-lasting narrowing of the lumen of the vessel of large-capacity cerebral arteries 
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at the base of the brain either close or distal to the bleeding site. And it is associated 
with reduced perfusion of the territories distal to the affected vessel.
Risk factors for vasospasm include:
1. The severity of bleeding
2. The proximity to the significant intracerebral blood vessels
3. The location and extent of blood on CT scan and radiologic grading scales
4. Age less than 50 years
5. Hyperglycemia
6. Glasgow Coma Scale score < 14
7.8.3 Mechanism
While the underlying mechanisms causing vasospasm are not fully understood, 
a proliferative inflammatory arteriopathy is the pathological feature of cerebral 
vasospasm. The intima shows disruption of the internal elastic lamina, and the 
media is thickened and fibrotic, with an increased smooth muscle cell proliferation. 
The adventitia is infiltrated with inflammatory cells, and the neuronal endings are 
impaired [14]. A significant predictor of vasospasm after SAH is the volume of blood 
present around the cerebral arteries of the circle of Willis which can be measured 
by transcranial Doppler (TCD), although it has been clearly demonstrated that 
prolonged exposure of cerebral arteries to perivascular blood is essential for the 
development of vasospasm. It is not possible to identify a single causative molecule as 
the culprit of vasospasm. However, vasospasm is believed to be produced by spasmo-
genic substances generated during the lysis of subarachnoid blood such as oxyhemo-
globin (a product of auto-oxidation of hemoglobin), nitric oxide, and endothelin-1. 
Those agents may be contributors to the pathological event of vasospasm.
Oxyhemoglobin may directly or indirectly trigger arterial vasoconstriction.
Oxyhemoglobin can also exert a scavenging effect on nitric oxide. It has been 
demonstrated that nitric oxide (a potent vasodilator) depleted during vasospasm 
and can stimulate endothelial cells to produce endothelin-1.
Endothelin-1 is the most potent and long-lasting vasoconstrictor effect, which 
is also associated with morphological changes, mimicking the delayed cerebral 
vasospasm. It has been shown that endothelin-1 levels are increased, not only in 
the cerebrospinal fluid during SAH and severe neuronal injury due to vasospasm or 
bleeding event. Moreover, endothelin levels change in neurological symptoms, but 
they do not predict vasospasm as assessed by transcranial Doppler. These observa-
tions suggest that endothelin-1 acts as a marker of cerebral ischemic injury [15, 16].
7.8.4 Diagnosis
7.8.4.1 Transcranial Doppler
It is a noninvasive tool and is useful for the detection and evaluation of vaso-
spasm. It can be performed at the bedside.
It used as a screening tool in high-grade World Federation of Neurological 
Surgeons (WFNS) scale patients in whom a neurological examination cannot be 
readily followed to identify those at higher risk [17].
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It is a highly specific noninvasive exam but has a low level of sensitivity, and it is 
operator-patient dependent, and its value is debated.
In 2004, the American Academy of Neurology conducted a systematic review 
of the literature and concluded that TCDs could be used reliably to screen for the 
presence of vasospasm in the only MCA. Their criteria for the diagnosis or exclu-
sion of vasospasm include flow velocity > 200 or 120 cm/s, respectively, significant 
increase in the flow velocities from day to day (>50 cm/s), and a Lindegaard ratio 
(MCAvelocity/ICAvelocity) > 6 [18].
7.8.4.2 CT scan
Noninvasive angiography with CT angiography (CTA) to confirm vasospasm for 
patients with elevated velocities on transcranial Doppler ultrasound. The plane CT 
scan is useful for ruling out other causes in the event of the occurrence of a deficit 
or worsening of the clinical state like rebleeding or ischemia. Several prospective 
cohorts showed a correlation between CTA and DSA in predicting vasospasm and 
that many unnecessary angiograms could be avoided by using CTA as a screening 
test [19, 20]. A recent meta-analysis found a sensitivity and specificity for CTA of 
80 and 93%, respectively [21].
7.8.4.3 MRI
MRI can help to identify and diagnose cerebral ischemia at the early stage.
7.8.4.4 Cerebral angiography
Cerebral angiography is the gold standard radiographic tool for the diagnosis 
of cerebral vasospasm. Angiography is used to identify patients with symptomatic 
vasospasm who might benefit from treatment.
In 30–70% of patients with SAH, angiographic vasospasm occurs, but it leads 
to clinically evident signs and symptoms in 20–30% of patients who experience 
delayed ischemic neurological deficits. About half of the symptomatic group of 
patients suffer severe permanent neurological dysfunction or death.
7.8.5 Treatment
The specific treatment of cerebral vasospasm helps improving cerebral blood 
flow to avoid delayed ischemic neurologic deficit by reducing ICP, optimizing the 
rate of cerebral oxygen demand, and enhancing cerebral blood flow with one of the 
following approaches: indirect pharmacological protection of brain tissue or direct 
mechanical dilation of the vasospastic vessel.
Nimodipine is the standard of care in aneurysmal SAH patients. Nimodipine 
60 mg every 4 hours can be used for all patients with aneurysmal SAH once the 
diagnosis is made for 21 days. Nimodipine is to be given orally or by nasogastric tube 
because intravenous administration causes serious adverse events, including death. 
The mechanism of benefit of nimodipine in SAH is unknown. Oral nimodipine 
is the only Class I evidence regarding cerebral vasospasm used in the publication 
of the AHA subarachnoid hemorrhage guidelines [22]. Early aneurysm treatment, 
HHH-therapy (hypertension, hypervolemia, and hemodilution), cerebral angio-
plasty, and selective intra-arterial vasodilator therapy were recommended based on 
Class II evidence.
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In summary, nimodipine was initially studied in SAH to prevent vasospasm. 
However, despite its vasodilatory effects on cerebral vessels, the evidence of 
nimodipine effects on the incidence of either angiographic or symptomatic vaso-
spasm is not convincing [23]. Nevertheless, nimodipine has been demonstrated to 
improve outcomes in SAH and is the agent of choice in these patients [23].
7.9 Calcium channel blockers for reversible cerebral vasoconstriction syndrome
Reversible cerebral vasoconstriction syndrome (RCVS) represents a group of 
conditions that show a reversible narrowing of the cerebral arteries with clinical 
manifestations that typically include thunderclap headache and less commonly 
neurologic deficits related to brain edema, seizure, or stroke. The clinical outcome 
is usually benign, although major strokes can result in severe disability and death in 
a minority. The pathophysiology of the abrupt-onset headache and the prolonged 
but reversible vasoconstriction is not known. Reversible angiographic narrowing 
suggests an abnormality in the control of cerebrovascular tone [24].
RCVS has been associated with a variety of conditions including pregnancy, 
migraine, use of vasoconstrictive drugs, neurosurgical procedures, hypercalcemia, 
unruptured saccular aneurysms, cervical artery dissection, and cerebral venous 
thrombosis. The diagnosis of RCVS is based upon the characteristic clinical, brain 
imaging, and angiographic features. Nimodipine and verapamil and brief courses of 
magnesium sulfate, serotonin antagonists, and dantrolene have been administered 
to relieve the vasoconstriction. Data from two prospective case series suggest that 
nimodipine does not affect the time course of cerebral vasoconstriction [25, 26]. 
However, nimodipine might relieve the number and intensity of headaches and has 
documented effects on the smaller vasculature not easily imaged by angiography. 
Calcium channel blockers can be discontinued after resolution of symptoms or 
angiographic abnormalities if they are used.
New Insight into Cerebrovascular Diseases - An Updated Comprehensive Review
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